Mining and analysis of adverse event signals of vandetanib based on the FAERS database.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Safety Pub Date : 2024-10-22 DOI:10.1080/14740338.2024.2418326
Ying Zhou, Na Li, Guowei Ma, Ning Su, Jiang Liu, Wenxi Yue, Rui Yin, Jie Chen
{"title":"Mining and analysis of adverse event signals of vandetanib based on the FAERS database.","authors":"Ying Zhou, Na Li, Guowei Ma, Ning Su, Jiang Liu, Wenxi Yue, Rui Yin, Jie Chen","doi":"10.1080/14740338.2024.2418326","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>By analyzing the signal mining of vandetanib AEs, it provides a reference for the rational clinical use of the drug.</p><p><strong>Methods: </strong>This study provides signal detection and analysis of AEs associated with vandetanib using the FAERS from Q2 2011 to Q1 2023.</p><p><strong>Results: </strong>Disproportionality analyses were conducted using the ROR and the MHRA method, with AEs categorized and described based on SOC and PT from the MedDRA. A total of 1,721 AEs reports identified vandetanib as the primary suspect. The analyses yielded 187 AEs signals across 20 SOCs categories, with 47 signals not previously reported in the vandetanib labeling. Additionally, the study analyzes factors influencing AEs. The results are as follows: There are significant differences in Investigations based on gender and nationality (<i>p</i> < 0.05); skin and subcutaneous tissue disorders and gastrointestinal disorders exhibit differences based on gender, age, and nationality (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Common AEs signals identified align with those documented in the drug labeling. However, AEs such as tumor lysis syndrome, skin discoloration, and pigmentary disorders, which are not listed in the labeling, warrant special attention. It is essential that abnormalities in patients' skin and laboratory indicators are closely monitored and addressed promptly to safeguard medication safety.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2418326","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: By analyzing the signal mining of vandetanib AEs, it provides a reference for the rational clinical use of the drug.

Methods: This study provides signal detection and analysis of AEs associated with vandetanib using the FAERS from Q2 2011 to Q1 2023.

Results: Disproportionality analyses were conducted using the ROR and the MHRA method, with AEs categorized and described based on SOC and PT from the MedDRA. A total of 1,721 AEs reports identified vandetanib as the primary suspect. The analyses yielded 187 AEs signals across 20 SOCs categories, with 47 signals not previously reported in the vandetanib labeling. Additionally, the study analyzes factors influencing AEs. The results are as follows: There are significant differences in Investigations based on gender and nationality (p < 0.05); skin and subcutaneous tissue disorders and gastrointestinal disorders exhibit differences based on gender, age, and nationality (p < 0.05).

Conclusion: Common AEs signals identified align with those documented in the drug labeling. However, AEs such as tumor lysis syndrome, skin discoloration, and pigmentary disorders, which are not listed in the labeling, warrant special attention. It is essential that abnormalities in patients' skin and laboratory indicators are closely monitored and addressed promptly to safeguard medication safety.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于 FAERS 数据库挖掘和分析凡德他尼的不良事件信号。
目的:通过分析凡德他尼AEs的信号挖掘,为临床合理用药提供参考:通过对凡德他尼AEs的信号挖掘分析,为临床合理用药提供参考:本研究利用FAERS对2011年第二季度至2023年第一季度与凡德他尼相关的AE进行信号检测和分析:使用 ROR 和 MHRA 方法进行了比例失调分析,根据 MedDRA 中的 SOC 和 PT 对 AE 进行了分类和描述。共有1,721份AEs报告确定凡德他尼为主要疑似药物。分析得出了 187 个 AEs 信号,涉及 20 个 SOCs 类别,其中 47 个信号以前未在凡德他尼标签中报告过。此外,研究还分析了影响 AEs 的因素。结果如下基于性别和国籍的调查存在重大差异(p p 结论:发现的常见 AEs 信号与药物标签中记录的一致。然而,诸如肿瘤溶解综合征、皮肤变色和色素失调等未在标签中列出的 AEs 值得特别关注。必须密切监测并及时处理患者的皮肤和实验室指标异常,以保障用药安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
期刊最新文献
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA adverse event reporting system. Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024. Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1